Effect of Low-Dose Vs Standard-Dose Valganciclovir in the Prevention of Cytomegalovirus Disease in Kidney Transplantation Recipients: A Systemic Review and Meta-Analysis

Valganciclovir is widely used to prevent post-transplant cytomegalovirus (CMV) infection in kidney transplant patients. However, the currently used dose remains controversial because the continuous use of this drug decreases kidney function and can induce leukopenia.

Source: Transplantation Proceedings - June 2, 2018 Category: Transplant Surgery Authors: S.D. Hwang, J.H. Lee, S.W. Lee, J.K. Kim, M.-J. Kim, J.H. Song Source Type: research